Oncoinvent A

Oncoinvent A EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncoinvent A (ONCIN.OL) as of Nov 7, 2026 is -158.33 M NOK. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -150.78 M NOK — a change of 5.01% (lower).

EBITDA

-158.33 MNOK

YoY

5.01%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncoinvent A is 2025 -158.33 M NOK. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncoinvent A was 2024 -150.78 M NOK. It decreases by 5.01% lower compared to the previous year.

The Oncoinvent A EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-194.33 M NOK
Jan 1, 2019
-203.59 M NOK
Jan 1, 2020
-260.37 M NOK
Jan 1, 2021
-313.15 M NOK
Jan 1, 2022
-304.75 M NOK
Jan 1, 2023
-191.60 M NOK
Jan 1, 2024
-150.78 M NOK
Jan 1, 2025
-158.33 M NOK
The Oncoinvent A EBITDA history
YEAREBITDAYoY
-158.33 MNOK+5.01%
-150.78 MNOK-21.30%
-191.60 MNOK-37.13%
-304.75 MNOK-2.68%
-313.15 MNOK+20.27%
-260.37 MNOK+27.89%
-203.59 MNOK+4.76%
-194.33 MNOK+5.90%
-183.52 MNOK+39.70%
-131.36 MNOK+80.58%
-72.75 MNOK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Oncoinvent A Stock analysis

What does Oncoinvent A do? Oncoinvent ASA is a radiopharmaceutical company based in Oslo, Norway, operating within the Health Care sector. Listed on 13 December 2024, the firm employs 46 people and focuses on developing alpha-emitting radiotherapeutics for cancer patients. Its primary product, Radspherin, is an alpha-emitting radioactive microsphere therapy designed to treat metastatic cancers in body cavities. This suspension of calcium carbonate microspheres labelled with Radium-224 targets residual micro-metastases on intracavitary surfaces and in liquids after surgery, aiming to spare deeper organs from harmful radiation doses. Oncoinvent A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oncoinvent A stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncoinvent A is -158.33 M NOK in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Oncoinvent A changed from -150.78 M NOK to -158.33 M NOK, representing a 5.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Oncoinvent A since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s NOK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Oncoinvent A historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Oncoinvent A

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Oncoinvent A